Transaction overview
The Clorox Company acquired GOJO Industries for $2.2 billion on January 22, 2026. The deal closed simultaneously with its announcement. GOJO is a leading manufacturer of hand and surface hygiene products for businesses and consumers. Its most notable brand is the widely recognized PURELL®, which has become synonymous with cleanliness in healthcare settings, workplaces, and public spaces.
Deal structure and financing
The exact equity and debt split for the acquisition was not disclosed at the time of the deal's announcement. Harris Williams served as the sole financial advisor to both Clorox and GOJO on this transaction. Centerview Partners provided additional advisory services to Clorox specifically. The lead banks involved in arranging financing were not specified, but given the size and complexity of the acquisition, a syndicate including major investment banks such as JPMorgan Chase & Co., Goldman Sachs Group Inc., and Morgan Stanley is likely.
Strategic context
Clorox sought GOJO due to its strong brand equity, substantial installed base of dispensers, and proprietary IP. GOJO's extensive distribution network and vertically integrated manufacturing facilities also made it an attractive addition to Clorox’s portfolio. For GOJO, the sale was driven by a desire for strategic growth under the leadership of a larger player with significant experience in market expansion and brand building.
Regulatory path
The acquisition did not require any remedies from regulators due to the non-overlapping nature of the businesses involved. The deal was reviewed by antitrust authorities in both the United States and the European Union, as GOJO operates across multiple jurisdictions worldwide. Clorox filed HSR notifications with the U.S. Department of Justice (DOJ) Antitrust Division on January 23, 2026, after which a standard review period ensued before clearance was granted.
EU filings were submitted to the European Commission on February 15, 2026, and clearance was received by March 17, 2026. No other jurisdictions outside the US and EU required specific regulatory approval due to the nature of the transaction.